Learning outcomes
By the end of this lesson you should be able to: state the diagnostic thresholds for diabetes and the categories of impaired glucose regulation; distinguish type 1, type 2 and the rarer causes at a clinical encounter; explain the natural history of type 2 diabetes as an insulin resistance with a progressive beta-cell failure; select the first-line and second-line treatments for type 2 diabetes given the comorbidity; describe the principles of the basal-bolus insulin regimen and of insulin titration; recognise hypoglycaemia, diabetic ketoacidosis and the hyperosmolar hyperglycaemic state; and list the microvascular and macrovascular complications and the surveillance that detects them.
Prerequisites
PHYS 101 and BCHM 101 (insulin, glucagon, carbohydrate and lipid metabolism), MED 301 lesson 3 (fluid, electrolyte and acid-base balance, and the anion gap) and lesson 4 (sepsis), plus PHRM 202 (insulin preparations and the oral agents).
The big idea
Insulin is the single hormone of the fed state: it moves glucose into muscle and fat, it stops the liver producing glucose, it stores fat and it builds protein. Remove it entirely and the body cannot use glucose for energy even though the blood is full of it, so it breaks down fat instead and produces ketones, and the patient loses weight and ketones while hyperglycaemic. Resist it and the tissues still take up glucose, but only when the insulin level is driven high enough, so the pancreas is overworked for years before it fails. That difference — absolute versus relative deficiency — is the boundary between the two commonest types, and it explains almost every difference in the presentation.
Diagnosis and classification
| Category | Diagnostic criteria | Note |
|---|---|---|
| Diabetes mellitus | A fasting plasma glucose of 7.0 millimoles per litre or more on two occasions; or a random glucose of 11.1 or more with symptoms; or a glycated haemoglobin (HbA1c) of 48 millimoles per mole (6.5 percent) or more; or a two-hour glucose of 11.1 or more on an oral glucose tolerance test | Any one criterion, confirmed on a second sample unless the patient is symptomatic — hyperglycaemia is not diagnosed on a single laboratory result |
| Impaired fasting glucose | A fasting glucose of 6.1 to 6.9 millimoles per litre | A prediabetic state that carries both a risk of conversion and a cardiovascular risk of its own |
| Impaired glucose tolerance | A two-hour glucose of 7.8 to 11.0 millimoles per litre on a tolerance test | The same significance, and a more powerful predictor of conversion than the fasting value |
| Prediabetes by HbA1c | A glycated haemoglobin of 42 to 47 millimoles per mole | Assessed because the value integrates the control over the preceding 8 to 12 weeks, and is unaffected by recent fasting |
| Type 1 diabetes | An absolute insulin deficiency: autoimmune beta-cell destruction (glutamic acid decarboxylase and islet cell antibodies), with a ketosis-prone patient and a low C-peptide | Not always childhood: the adult-onset latent autoimmune form (LADA) presents in adulthood and is diagnosed by antibodies and insulin requirement |
| Type 2 diabetes | Insulin resistance with a progressive beta-cell failure: the onset is later, obesity and acanthosis nigricans are common, and there is no ketosis at presentation | Accounts for about nine tenths of all cases; a family history in a first-degree relative is present in most |
| Monogenic and secondary | Maturity-onset diabetes of the young (MODY) in a young non-obese patient with a strong autosomal-dominant family history; and the secondary causes — pancreatitis, pancreatectomy, cystic fibrosis, Cushing's syndrome, acromegaly, thyrotoxicosis, haemochromatosis, glucocorticoid or antipsychotic therapy | Recognising them changes the treatment: a steroid-induced diabetes is treated by reducing the steroid, and MODY by oral sulphonylureas rather than insulin |
| Gestational diabetes | A glucose intolerance first recognised in pregnancy, screened with a fasting glucose and a tolerance test | Resolves after delivery in most, but predicts type 2 diabetes and requires a follow-up test |
NoteHbA1c is unreliable where the red cell turnover is altered: anaemia, haemoglobinopathy, recent transfusion, pregnancy and chronic kidney disease all make the value falsely low or high. Glucose, or a fructosamine, is used instead in those settings.
The natural history of type 2 diabetes
The disease begins with insulin resistance, usually in the liver, muscle and fat, in a patient with a genetic tendency and excess adipose tissue. The pancreas compensates by secreting more insulin, so the glucose remains normal while the insulin level is high: this is the hyperinsulinaemic phase that precedes the diagnosis. Over years the beta cells, which cannot sustain the output, decline in function — first post-prandially, then fasting — and the glucose rises in that order.
| Stage | Glucose | Insulin | Clinical implication |
|---|---|---|---|
| Compensated resistance | Normal | High | Normal glucose tolerance with a high insulin; a prediabetic patient with features of the metabolic syndrome |
| Failure of first-phase secretion | Normal fasting, raised post-prandially | Rising then plateauing | Prediabetes, detected only on a tolerance test or by an HbA1c in the higher part of the range |
| Beta-cell decline | Raised | Falling | Diabetes, and the point at which therapy escalates: metformin, then the additional classes as the decline continues |
| Established insulin deficiency | Raised despite oral therapy | Low | Insulin is needed, not because of the diagnosis but because the beta cell has failed |
This natural history is why the type 2 patient is told the diagnosis is progressive, and why each new agent in the pathway buys the beta cell time rather than replacing it. It is also why the initial therapy in a patient presenting with a glucose of 20 and weight loss may be insulin for a period: the glucose toxicity itself suppresses the beta cell, and lowering it can restore function.
Treatment of type 2 diabetes
| Class | Drugs | How it works | Where it belongs |
|---|---|---|---|
| Biguanide | Metformin | Reduces hepatic glucose production and improves peripheral insulin sensitivity | First-line for most patients, and it is weight-neutral; contraindicated at an estimated glomerular filtration rate below 30, and given in a reduced dose below 45; withdrawn in acute illness and before iodinated contrast |
| SGLT2 inhibitor | Dapagliflozin, empagliflozin | Blocks glucose reabsorption in the proximal tubule, glycosurising the patient | For patients with established atherosclerotic disease, heart failure with reduced ejection fraction or chronic kidney disease: it reduces cardiovascular death and renal decline, and it does not cause hypoglycaemia alone |
| GLP-1 receptor agonist | Semaglutide, liraglutide, dulaglutide | Glucose-dependent insulin release, suppression of glucagon, slowed gastric emptying, and weight loss | For patients with atherosclerotic disease, obesity, or where a weight reduction is the target; it reduces events in the highest-risk patients; it causes nausea and, rarely, pancreatitis |
| DPP-4 inhibitor | Sitagliptin, linagliptin | Prolongs endogenous GLP-1 activity | A weight-neutral oral option, well tolerated, with little effect on cardiovascular outcomes |
| Sulphonylurea | Gliclazide, glimepiride | Closes the potassium channel of the beta cell and stimulates insulin release irrespective of the glucose | A cheap and effective option, but it causes hypoglycaemia and weight gain, so it is used where cost or bioavailability dictate |
| Thiazolidinedione | Pioglitazone | Improves peripheral insulin sensitivity | Useful in insulin-resistant patients, but causes weight gain, fluid retention and heart failure, and it increases the fracture risk |
| Insulin | Basal, then basal-bolus, or a biphasic mixture | Replaces what the beta cell can no longer produce | Introduced when the HbA1c is well above the target (usually above 75 millimoles per mole) with symptoms, when there is catabolism, in pregnancy where the oral agents do not control it, or when oral therapy has failed |
The choice of the second or third agent is no longer simply about the glucose: it is driven by the cardiovascular and renal disease the patient already has. In a patient with heart failure or established atherosclerotic disease the SGLT2 inhibitor or the GLP-1 receptor agonist is added irrespective of the HbA1c, because the outcome benefit is independent of the glucose lowering. In a patient without those conditions, where cost and simplicity dominate, metformin with another oral agent is entirely appropriate.
Insulin therapy
| Regimen | How it is constructed | Indication |
|---|---|---|
| Basal-bolus | A long-acting analogue (glargine, detemir, degludec) or isophane insulin at night or twice daily, plus a rapid-acting analogue before each meal | The physiological regimen for type 1 diabetes and for a type 2 patient needing a flexible regimen; it is the basis of the dose-adjustment technique |
| Twice-daily biphasic (premixed) insulin | A fixed mixture of a rapid and an intermediate-acting insulin before breakfast and supper | A simpler, less flexible option for a patient with a routine, who cannot manage four injections |
| Once-daily basal insulin added to metformin | A long-acting insulin at night, titrated against the fasting glucose | The usual first step when oral therapy in type 2 diabetes fails |
| Continuous subcutaneous infusion | A pump delivering a continuous basal rate with mealtime boluses | For patients with a tight control target, a dawn phenomenon, or recurrent hypoglycaemia, and it requires carbohydrate counting |
| Correction and carbohydrate counting | The correction dose for a raised glucose, and the meal dose for the carbohydrate to be eaten | The education that makes the regimen safe, and it is taught before the patient is discharged after a first diagnosis of type 1 diabetes |
Titration is a self-correcting loop rather than a dose set at the clinic. The fasting glucose tells you the basal dose, and the post-meal glucose tells you the meal doses: increase the basal by two units every three days until the fasting value is in range, unless nocturnal hypoglycaemia intervenes; and increase the meal dose for a specific hyperglycaemic reading after a specific meal. Sick-day rules accompany it: the insulin is never stopped when the patient is ill, and the carbohydrate is replaced if the glucose falls.
Acute complications
| Hypoglycaemia | Diabetic ketoacidosis | Hyperosmolar hyperglycaemic state | |
|---|---|---|---|
| Mechanism | Insulin or a secretagogue exceeding the glucose available | Absolute insulin deficiency with counter-regulatory hormone excess | Relative deficiency, usually precipitated by illness, in a patient who can still secrete enough insulin to prevent ketosis |
| Typical patient | Any patient on insulin or a sulphonylurea | Usually type 1, often after an infection, a missed dose or a new diagnosis | Usually an elderly type 2 patient with an intercurrent infection, a new drug or a missed dose |
| Presentation | Tremor, sweating, hunger, palpitations, then confusion, behavioural change and seizures if unrelieved | Slow-onset polyuria, polydipsia, vomiting, abdominal pain, Kussmaul breathing, ketotic breath, dehydration | Profound dehydration, drowsiness or coma, with a glucose above 33.9 millimoles per litre |
| Glucose | Below 4.0 millimoles per litre | Usually 11.0 to 30.0 | Usually very high, above 33.9 |
| Ketones and pH | Normal | Ketonuria and ketonaemia with a pH below 7.30 and a raised anion gap | Minimal ketones, pH above 7.30 |
| Osmolality | Normal | Normal or mildly raised | Above 320 milliosmoles per kilogram |
| Mortality | Rare but a cause of death in the young and in the old | Low with treatment (under 1 percent in the young), high in the elderly | High, from the dehydration and the precipitating illness (10 percent or more) |
| Immediate treatment | Oral glucose or a glucose gel if conscious; intramuscular glucagon or intravenous dextrose if not | Fluid resuscitation with isotonic saline, an insulin infusion, potassium replacement, and treatment of the precipitant | Very large-volume fluid resuscitation with isotonic saline, a low-dose insulin infusion, and anticoagulation for the thrombosis risk |
Watch outSGLT2 inhibitors cause euglycaemic ketoacidosis: a ketoacidosis with a virtually normal glucose, which is missed because the glucose is not high. It is precipitated by illness, surgery or fasting, so the drug is stopped during those events and in the perioperative period, and it is not licensed for type 1 diabetes.
NoteIn treating diabetic ketoacidosis the potassium may fall rapidly as the acid is corrected and insulin drives it into the cells. If the potassium is below 3.3 millimoles per litre, insulin is withheld until it has been replaced — because depriving a hypokalaemic patient of insulin while they are acidotic is dangerous.
Chronic complications and their surveillance
| Complication | Mechanism | Surveillance and treatment |
|---|---|---|
| Retinopathy | Microvascular damage to the retinal circulation, with microaneurysms, exudates and neovascularisation | Annual retinal screening from the point of diagnosis; pan-retinal photocoagulation and anti-vascular endothelial growth factor therapy for the proliferative stage |
| Nephropathy | Glomerular hyperfiltration and basement-membrane thickening, then glomerulosclerosis: albuminuria preceding a falling filtration rate | An annual urine albumin-to-creatinine ratio and a serum creatinine; an ACE inhibitor or an angiotensin receptor blocker for albuminuria, plus glycaemic and blood pressure control |
| Neuropathy | Distal symmetrical sensory loss (the stocking and glove pattern), a mononeuropathy, and an autonomic neuropathy (impotence, postural hypotension, gastroparesis, silent myocardial infarction) | Annual examination with a 10-gram monofilament and vibration sense; strict feet care, and a review for neuropathic treatment |
| Macrovascular disease | Accelerated atherosclerosis: myocardial infarction, stroke and peripheral arterial disease — the commonest cause of death in diabetes | Blood pressure below 130/80, a statin, an antiplatelet in established disease, smoking cessation, and a low threshold for symptoms |
| Foot ulceration | Neuropathy is combined with vascular disease and infection, so a trivial injury ulcerates and does not heal | Annual foot examination with a photograph record; a multidisciplinary foot clinic for any ulcer; the patient with a red, hot, swollen foot and fever may have osteomyelitis |
| Infection risk | Impaired neutrophil function and the vasculature | Immunisation against influenza, pneumococcus and COVID-19, and rapid treatment of cellulitis and urinary infection |
| Target | Value | Comment |
|---|---|---|
| Glycated haemoglobin | 48 millimoles per mole (6.5 percent) for most; 53 (7 percent) where hypoglycaemia is a risk | Individualised: a tighter target in a young patient with early disease, a looser one in the elderly or with long duration |
| Blood pressure | Below 130/80 millimetres of mercury | Treated with an ACE inhibitor or an angiotensin receptor blocker first, for the renal protection as well as the pressure |
| Lipids | A statin at the highest tolerated dose, or an added ezetimibe if the target is not met | Almost every patient with type 2 diabetes over 40 is treated, and all type 1 patients with albuminuria or another risk factor |
| Aspirin | Not primary prevention generally | Reserved for those with established vascular disease |
Watch outNever stop insulin in a type 1 patient who is unwell, and never omit it because the glucose is normal or the patient is not eating. The basal insulin is continued at the usual dose, and the carbohydrate is replaced by fluids or glucose, because a patient on basal insulin who is not eating has enough insulin to become hypoglycaemic.
Common mistakes
Watch outDiagnosing type 2 diabetes in a lean, young, ketotic patient because the presentation looks like a bad flu. A ketotic, dehydrated, catabolic patient has type 1 diabetes until antibodies and a C-peptide prove otherwise, and insulin is started immediately.
Watch outWithholding insulin in diabetic ketoacidosis because the potassium is low. The reverse: insulin drives potassium into the cells and lowers the serum level further, so a potassium below 3.3 millimoles per litre is replaced first and then insulin is started — the acid is still waited on.
Watch outContinuing metformin and an SGLT2 inhibitor through acute illness, contrast imaging and surgery. Metformin accumulates in a failing kidney and can cause lactic acidosis, and an SGLT2 inhibitor causes euglycaemic ketoacidosis: both are held at those events with a documented restart date.
Watch outTreating a raised HbA1c in isolation. The cardiovascular and renal outcomes are driven by blood pressure, lipids and smoking as much as by glucose, so all four are managed at every visit.
Check your understanding
Why does the same hyperglycaemia produce ketoacidosis in type 1 diabetes and a hyperosmolar state in type 2 diabetes?
A patient with type 2 diabetes has an estimated glomerular filtration rate of 36 and is taking metformin. What action is required?
Which drug classes should be considered in a patient with type 2 diabetes, reduced ejection fraction and albuminuria, regardless of the glycated haemoglobin?
Multiple choice
Which finding confirms a diagnosis of diabetes mellitus in an asymptomatic patient?
A patient with type 2 diabetes and an estimated glomerular filtration rate of 55 develops heart failure with a reduced ejection fraction. Which agent should be added irrespective of the HbA1c?
A 19-year-old with a two-week history of vomiting, rapid weight loss and a glucose of 27 millimoles per litre has a pH of 7.10 with ketonaemia. Which is the immediate priority after an intravenous cannula?
Which combination best describes the hyperosmolar hyperglycaemic state?
Which is a recommended annual surveillance test in a patient with type 2 diabetes?
Module summary and next
Diabetes is either an absolute or a relative deficiency of insulin, and that division separates the two commonest forms in the presentation, the treatment and the emergency. Type 1 is managed by insulin replacement and education; type 2 is managed by metformin and by the agent that matches the comorbidity, with insulin added as the beta cell fails. Surveillance is aimed at the complications the patient cannot feel — the retina, the kidney and the foot — because the presence of insulin is what allows glucose into the tissues, and its absence is what destroys them.
Next module: nephrology, haematology and infectious disease, beginning with renal disease and acute kidney injury, which is both a consequence of diabetes and one of its acute emergencies.